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Summary
Background: The primary aim was to induce a high number
of pCR in early (FIGO IC, KB + C) - and advanced (FIGO
rQ-IV) - stage ovarian cancer with a surgery plus 4 cycles of
cisplatin and melphalan (PAMP) regimen. The second objec-
tive was to prevent relapse with WAR in patients in remission
after chemotherapy.
Patients and methods: 218 eligible patients were treated
after staging laparotomy with cisplatin 80 mg/sqm i.v. on day
1 and melphalan 12 mg/sqm i.v. on day 2 q 4 weeks. Re-
sponse was verified by second-look laparotomy. WAR was
carried out with the open field technique on a linear accele-
rator (daily dose: 1.3 Gy, total dose: 29.9 Gy) in patients with
pathological or clinical CR or pathological PR with micro-
scopical residual disease.
Results: 146/218 patients (67%, 95% CI: 61%-73%)
responded to PAMP: 56 (26%) achieved pCR, 24 (11%),
cCR, 56 (26%) pPR and 10 (5%) cPR (c = clinical, p =
pathological). Multivariate analyses revealed that in ad-
vanced stages (92 cases in remission), the achievement of
pCR was the most important factor for longer time to failure
(TTF) and survival. Only 51/118 (43%) patients in remission
received WAR. Early-stage patients <— 55 years were more
likely to have WAR than patients older than 55 years (77%
vs. 23%; p = 0.02). Advanced-stage patients with cCR were
less likely to be irradiated than patients with pCR or pPR
(10% vs. 51%; p - 0.003). Toxicity of PAMP was acceptable
with 10% of WHO grade 4 hematologic toxicity. Acute
hematological toxicity of WAR caused interruption (33%) or
incompleteness (33%) of irradiation in the majority of
patients.
Conclusions: PAMP is an effective treatment for ad-
vanced ovarian cancer with a 67% response rate after 4
cycles. For the majority of patients in remission, WAR as a
consolidation treatment was hardly feasible. For these
patients new treatment modalities to consolidate remission
are needed.
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Introduction
Ovarian cancer is currently the second most common
cause of death from malignancies in the female genital
tract in the Western world. Refined surgical techniques
and platinum combinations have increased the number
of patients achieving complete remission and a pro-
longed progression-free interval, but only around 20%
will survive in the long run [1]. Preliminary reports of
patients with early-stage and poor prognostic features
(grade HI, positive peritoneal washing, ascites) support
the use of chemotherapy [2]. The standard chemother-
apy for advanced (stage HI-IV) ovarian cancer consists
of 6 cycles of cisplatin or carboplatin plus cyclophos-
phamide. With these two regimens, similar pathologi-
cally proven response rates can be obtained [3]. Cis-
platin and melphalan are equally effective. In a large
single-arm study conducted by the SAKK (Swiss
Group for Clinical Cancer Research), a pathological
response rate of 59% was achieved with 6 cycles of this
combination [4].
Whole-adominal radiotherapy (WAR) was mainly
used for palliation until the reports by Dembo et al.
proved its usefulness for improving survival in patients
with small or no residual disease after the first opera-
tion [5]. The open field technique became the standard
approach and proved to be equally effective but less
toxic and easier to apply than the moving-strip [6].
Several single-arm studies of sequential multimodality
therapy including chemotherapy, second-look surgery
and radiotherapy [4, 7-8] have been published since
the report of Dembo. It remains difficult to draw con-
clusions from these non-randomized studies.
In the previous SAKK trial [4], the actuarial 3-year
time to progression after second-look operation for
patients who achieved complete remission and under-
went radiotherapy for consolidation of response was
83% vs. 49% for patients without radiation.
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We therefore decided in 1985 to study the feasibility
and efficacy of WAR after short-course chemother-
apy. Our aims were to induce a high number of patho-
logically verified complete remissions with surgery plus
4 cycles of cisplatin and melphalan and to prevent
relapse with WAR in a target population of patients
in remission (pathologically and clinically complete
remissions and patients with microscopic residual dis-
ease).
Patients and methods
Eligibility
The eligibility criteria included: histologically confirmed epithelial
carcinoma of the ovary (with the exception of rare clear cell carci-
noma and malignant mixed Mullerian tumors); International Fed-
eration of Gynecology and Obstetrics (FIGO) stage IC, HB-C, m or
IV; no prior treatment; upper age limit of 70 years; ECOG perfor-
mance status < 3; adequate bone marrow, hepatic and renal function;
no history of prior malignancy other than basal or squamous cell
skin cancer or adequately treated squamous cell cancer of the cervix
in situ.
Patients were classified after initial surgery as having unresect-
able residual disease < - 2 cm or >2 cm. Lymph node and gastro-
intestinal involvement were judged by either histology or obvious
intraoperative presentation.
A pathology review of histological diagnosis was performed by a
central panel after completion of the study. The histological typing
of the epithelial tumors was done in accordance with the WHO clas-
sification of ovarian tumors (1973). The histological grading of the
primary tumors was analogous to the FIGO grading for endometrial
carcinomas.
Baseline examinations included a complete physical examina-
tion, blood count, urine test, measurement of CA-125, chest X-ray
and computed tomography. Oral informed consent was obtained
from all patients before initiation of therapy.
Treatment
Chemotherapy
Patients received 4 cycles of PAMP: cisplatin (P) 80 mg/m2 intra-
venously (i.v.) on day 1 with prehydration and forced diuresis, mel-
phalan (PAM) 12 mg/m2 i.v. on day 2. The treatment started within
10—30 days after surgery and was repeated every 28 days. Anti-
emetics were administered at the discretion of the treating physician.
Toxicity was graded according to the WHO classification [9].
Response evaluation was performed after 4 cycles. Patients with
no signs of disease or with partial remission in whom debulking
could be performed underwent a restaging laparotomy. It was
planned for patients with partial remission or no change to receive
an additional 2-3 cycles. Patients with clinically or pathologically
complete remission or with microscopical residual disease after 4-6
cycles were scheduled for WAR.
Radiotherapy
WAR was carried out by means of the open field technique with the
entire abdomen as a target volume on a linear accelerator with the
recommended energy of 8 MeV (energies from 6—16 MeV were
allowed). A daily prescription point dose of 1.3 Gy was admin-
istered by opposed fields in 5 fractions per week up to a total dose
of 29.9 Gy.
Radiotherapy was to begin within a maximum of 6 weeks after
second-look laparotomy. WAR was interrupted if WBC were
<2.5 x 1071 or platelets <70 x 109/l. WAR was reintroduced after
interruption if WBC were >3.5 x 1071 and platelets 150 x 109/l. In
instances of interruption < - 5 days, 23 fractions were still applied,
and in instances of interruption of >5 days, 24 fractions were
applied. If the interruption was > 10 days, 25 fractions were given. If
the interruption lasted longer than 20 days, continuation of radio-
therapy was left to the judgment of the therapist.
Documentation of the treatment was sent to a central quality
review institution.
Response
WHO criteria were adopted [9] for clinical response evaluation.
Clinically assessed response was, whenever possible, documented
by second-look surgery.
Patients
Two hundred sixty-two patients were registered from 15 July 1985
to 22 November 1991. Forty-four patients were excluded from this
analysis. They were: 7 ineligible cases (clear cell carcinoma, FIGO
stage IB, tuba carcinoma, previous breast cancer, PS - 3 and age
>70 years), 34 patients identified by the central review as having
borderline tumors or other histologies and 3 'major' protocol viola-
tions.
Table 1 reports the patient characteristics. Displayed histological
type and tumor grading are as assessed by the central pathology
review. Unclassified epithelial carcinomas are included in the group
of undifferentiated tumors. About 80% of the patients started
PAMP within 1 month after surgery; the maximum delay was 2
months.
Table 1. Eligible patients characteristics and features of disease.
Histology
Serous
Endometrioid
Undifferentiated
Mucinous
Unknown at review
Grade
1
2
3
Unknown at review
FIGO stage
IC
HBand C
in
IV
Performance status
0
1
2
Type of surgery
Incomplete
Complete
Residual tumor after first surgery
0
< - 2 c m
>2cm
Total
Frequency
142
13
52
6
5
12
43
135
28
17
17
146
38
94
99
25
75
143
43
90
85
218
Percent
65%
6%
24%
3%
2%
6%
20%
62%
13%
8%
8%
67%
17%
43%
45%
12%
34%
66%
20%
41%
39%
67
Statistics
All patients entered into the study were followed until death or at
least August 1993. The median follow-up was 5 years (range: 20-93
months). The end points were: remission rate, pCR rate, progres-
sion-free survival, time to failure (TTF), overall survival, toxicity and
morbidity of PAMP and of WAR. Allocation to WAR was not based
on randomization but on the choice of the treating physician.
Results concerning efficacy based on comparisons between out-
come of WAR vs. no WAR have therefore be interpreted with cau-
tion.
Progression-free survival and survival time were calculated from
the first day of treatment TTF was defined as the time from second-
look to the first sign of progression, second cancer or death. For pa-
tients without second-look, the earliest data of achieving best
response was considered. The distributions of progression-free sur-
vival, TTF and survival were estimated by the method of Kaplan and
Meier [10]. The prognostic importance of variables was assessed
using both univariate and multivariate methods [11, 12]. Hazard
ratio (HR, failure/death) values >1 (<1) indicate an increased
(reduced) risk of failure/death as compared to the appropriate
reference group. Logistic regression was used to simultaneously
adjust for the effects on WAR completion of several explanatory
variables. All reported p-values are for 2-sided tests.
Results
Two hundred eighteen patients were assessed for re-
sponse to chemotherapy, progression-free and overall
survival. The median progression-free survival was 17
months. At 3 years 28% (95% CI: 22%-34%) and at 5
years 17% (ll%-23%) were alive and progression free.
The median overall survival was 30 months. 148 pa-
tients died (146 of disease and 2 of myocardial infarc-
tion before relapse). At 3 years 43% (36%-50%) and
at 5 years 26% (19%-33%) were still alive.
Overall response
Overall, 146/218 patients (67%, 95% CI: 61%-73%)
showed response to chemotherapy. The estimated over-
all CR rate (pCR and cCR) was 37% (95% CI: 31%-
43%). Seven patients reached pCR and 3 reached cCR
after more than 4 cycles. Table 2 summarizes the
responses by early- (FIGO I—H) and advanced-stage
(FIGOm-IV) groups.
Table 2. Response by stage groups.
Early stages
(FIGO I—10
Advanced stages
(FIGO m-IV)
Response Frequency Percent Frequency Percent
CR
pCR
cCR
PR
NC
PD
25
19
6
1
4
4
74%
56%
18%
3%
12%
12%
55
37
18
65
29
35
30%
20%
10%
35%
16%
19%
In a total of 147/218 (67%) patients response was
pathologically verified (12 of them had second-look
after >4 cycles). In the remaining 71 cases (33%)
response was only clinically evaluated. As expect-
ed, the comparison between the 2 methods confirmed
that clinical assessment did not always reflect the
actual situation, as 30% of the pathologically veri-
fied responses were inferior to those clinically docu-
mented.
For further analyses of WAR and prognostic factors,
118 patients in remission (56 pCR, 27 cCR and 35
pPR with microscopic residual disease) were con-
sidered. Their characteristics according to stage group
and WAR are displayed in Table 3. Radiotherapy was
performed only in 51/118 (43%) patients in remission
despite the protocol indication. The main reasons were
refusal and recommendation of the treating physician.
The rate of irradiation was similar in the two stage
groups: 13/26 (50%) in early vs. 38/92 (41%) in ad-
vanced-stage, respectively (p - 0.50). However, young
(<55 years) early-stage patients were more likely to be
irradiated: 10/13 (77%) received WAR and 3/13
(23%) did not receive it (p = 0.02). Moreover, ad-
vanced-stage patients with clinical evaluation alone
(i.e., cCR) were less likely to be irradiated than patients
with pathological evaluation: 10% vs. 51% (p - 0.003)
(see Table 3).
Table 3. Characteristics of patients in remission by stage and WAR.
Early stages Advanced stages
(FIGO I-n) (FIGO III-IV)
Not Irra- Not Irra-
irra- diated irra- diated
diated diated
Performance status
0 8 9 21 19
1-2 5 4 33 19
Age (years)
< - 5 5 3 10 21 15
>55 10 3 33 23
Histology
Serous 9 9 31 25
Non-serous 4 4 23 13
Grade
1-2 5 6 9 8
3 8 7 38 27
Unknown at review 0 0 7 3
Residual after first surgery
< - 2 c m 12 11 33 29
>2cm 1 2 21 9
Lymph node involvement
No 10 7 18 14
Yes or unknown 3 6 36 24
Pathological response
pCR 9 10 17 20
pPR 0 1 18 16
Not evaluated (cCR) 4 2 19 2
Total 34 184 Total 13 13 54 38
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Fig. i. Advanced stage, TTF by pathological response.
Patients in remission: Time to failure
The median TTF of all patients in remission was 23
months with 76/118 recurrences thus far. At 3 years
38% (95% CI: 28%-48%) and at 5 years 29% (19%-
39%) were still in remission. No second cancers have
been observed thus far. The low number of recurrences
[8] did not allow a reliable evaluation of TTF in early
Stages.
Advanced stage (FIGO HI-IV). The most important
factors in predicting prolonged TTF were residual dis-
ease after first surgery <= 2 cm, no lymph node in-
volvement at diagnosis and achievement of pCR. TTF
curves by response are displayed in Fig. 1. Three-year
percentages (95% a ) were: 47% (29%-65%) for pCR,
31% (10%-42%) for cCR and 15% (3%-27%) for pPR
with microscopically residual disease. No significant
effect of WAR could be observed. The multivariate
analysis adjusted for age, grade and residual disease
confirmed the role of achievement of pCR (HR •= 0.48,
95% CI: 0.28-0.82, p - 0.007) and that WAR did not
significantly predict TTF.
Seventy-six/118 patients in remission have relapsed
so far. Sixty-one were found to have diffuse peritoneal
carcinosis + / - distant metastases (23 with WAR and 38
without). In 13 patients relapse occurred in the pelvis
+ / - distant metastases (7 with WAR and 6 without); for
8 of them, pelvic relapse was verified by laparotomy.
Two patients had distant metastases without sign of
disease in their abdomen (1 with WAR and 1 without).
There was no significant difference in relapse sites
between irradiated and non-irradiated patients.
Patients in remission: Survival
The median survival for all patients in remission was
50 months. Fifty-nine patients died of tumor and 1
died without relapse of myocardial infarction. At 3
years 63% (95% CI: 53%-73%) and at 5 years 43%
(31%-55%) were still alive. As for TTF, the low num-
ber of events did not allow a reliable evaluation in early
stages.
Advanced stage (FIGO III-IV). The most important
factors in predicting prolonged survival were low
grade, no lymph node involvement at diagnosis and
achievement of pCR. Three-year percentages (95% CI)
were: 76% (62%-90%) for pCR, 53% (31%-75%) for
cCR and 43% (25%-61%) for pPR with microscopi-
cally residual disease. No significant effect of WAR
could be observed. The multivariate analysis adjusted
for age, grade and lymph node involvement confirmed
the role of achievement of pCR (HR = 0.31, 95% CI:
0.16-0.61, p - 0.0004) and that WAR did not signifi-
cantly predict survival.
Radiotherapy
WAR was performed in 51/118 (43%) patients in re-
mission. It was completed for 34 patients (67%); 17 of
them had interruptions. WAR was not completed,
mainly due to hematological toxicity, in 17 patients
(33%). One of them received only irradiation of the
pelvis (protocol violation). Advanced stages had a
lower completion rate (61%) than early stages (85%;
p = 0.18). Median doses were: 29.9 Gy (complete), 31.2
Gy (complete with interruptions) and 15.6 Gy (incom-
plete). The two stage groups received the same doses.
Forty-one patients were irradiated after 4 cycles and 10
after 6-7 cycles of PAMP. A logistic regression analysis
was performed to assess the effect of various factors on
completeness (with or without interruptions) of WAR.
Significantly higher WAR completion rates were ob-
tained for early-stage (I—II), small (<- 2 cm) residual
disease at diagnosis and previous higher doses of cis-
platin. Significantly lower WAR completion rates were
found for patients experiencing toxicity (nausea/vomit-
ing and neurological) during chemotherapy. Previous
second-look surgery was not significantly related to the
WAR completion rate.
Toxicity and side effects
Chemotherapy
Two hundred fifty-two patients started chemotherapy
and were evaluated for toxic effects of PAMP for a total
of 960 cycles. Two hundred twenty-four patients (89%)
received a minimum of 4 cycles of PAMP. Sixteen
minor protocol violations occurred (6%) and were
mainly due to: fewer cycles because of refusal, substitu-
tion of cisplatin with carboplatin after 1-2 cycles and
substitution of melphalan by cyclophosphamide be-
cause of toxicity.
The median dose of cisplatin was 78 mg/m2 (range
20-106 mg/m2). In 62% of the cycles cisplatin was
given at a dosage of >75% of the planned dose. The
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median dose of Melphalan was 12 mg/m2 (range
10-63 mg/m2). In 75% of the cycles melphalan was
given at a dosage >75% of the planned dose. Five pa-
tients erroneously received overdosages of melphalan:
they received more than 30 mg/m2 and developed
transient severe myelosuppression but all eventually
recovered.
Hematological toxicity was the major acute toxicity.
Leukocyte counts had a median nadir of 2.1 x 109/l
(range: 1.0-4.2 x 109/l). The leukocyte count was less
than 4.0 x 10V1 at least once for 248/250 patients.
The median platelet nadir was 86 x 109/l (range:
2-269 x 10 Yl). Platelet counts were <10 x 109/l for
10 patients (3 of them had received overdosages of
melphalan). The median hemoglobin nadir was 9.5 g/dl
(range, 5.2 to 12.3 g/dl).
Radiotherapy
Acute side effects. 17/51 patients temporarily inter-
rupted WAR mainly because of transient hematotoxic
side effects. In addition, another 15 patients were un-
able to complete WAR due to hematological toxicity.
The median hemoglobin nadir was 10.8 (range: 9.1-
13.3) g/dl, and the median leukocyte count nadir was
2.4 x 1071 (range: 1.2-4.3 x 1071). The median plate-
let nadir was 85 x 109/l (range: 19-172 x 10Y1).
Seventeen percent of the patients had grade 2-3 diar-
rhoea and 20% grade 2-3 nausea. No important skin
reactions were observed.
Long term side effects. Twelve patients developed side
effects with delayed onset. Ten patients developed
gastrointestinal side effects: 4 patients complained of
chronic 'mild' constipation and 1 of chronic 'mild' diar-
rhoea; 3 patients developed chronic 'moderate' sub-
total bowel obstruction many months before a relapse
was documented; 1 patient developed bowel occlusion
needing surgery (no evidence of recurrence); and 1
patient suffered from disabling bowel bleeding after
additional pelvic irradiation for first relapse. Repeated
colonoscopies demonstrated enteropathy due to radia-
tion damage. In another 2 patients basal lung tissue
changes were documented in repeated chest X-rays and
attributed to previous irradiation.
Discussion
This study was designed to address the role of short-
course cisplatin-based chemotherapy in patients with
early and advanced ovarian cancer and the feasibility
and role of WAR in patients in remission. The overall
response rate was 67% with 26% of the patients
achieving pCR. This is comparable to other data in the
literature for cisplatin-based chemotherapies delivered
over 6-12 cycles [4, 13]. Sixty-seven percent of the
responses were pathologically evaluated. Interestingly,
few patients reached pCR or cCR after more than 4
cycles. The data showed that best response with plati-
num regimens was obtained in an early phase of treat-
ment and that further cycles did not necessarily eradi-
cate persistent disease. Hainsworth suggested that,
after 6 cycles, patients should be considered for inves-
tigational approaches [14]. We would recommend this
approach even after 4 cycles. Toxicities observed with
PAMP were mild to moderate and well manageable.
Hematological toxicity grade 4, which may be attribut-
ed to melphalan, occurred in about 7%—10% of the
cases, which is also a rather low rate.
The median overall progression-free survival of the
218 patients and the median overall survival were
favorable compared to results for 8 cycles of platinum-
based chemotherapies [15]. A direct comparison of
outcome, however, may be misleading as we included
early stages and the planned cisplatin dose (80 mg/m2)
was higher than in other trials.
At 5 years 29% of the 118 patients in remission were
without relapse and 43% were alive. In stage HI-TV, we
observed a longer TTF for those achieving pCR, with
residual disease < - 2 cm at first surgery and without
lymph node involvement. With the limitations of prog-
nostic variables analysis [16] in mind, we observed that
in stage m-rV, the achievement of pCR was an inde-
pendent predictor for TTF as well as for survival. Pa-
tients in pPR with microscopic residual disease had a
worse prognosis than patients in CR, as in the long-term
analysis of Neijt et al. [1]. In our study, residual disease
after first surgery could not be identified as an inde-
pendent prognostic variable. Its importance has already
been diminished in the overview of Levin et al. [16].
The second aim of this trial was to study the feasi-
bility and role of WAR in patients in remission (pCR,
cCR and PR with pathologically documented micro-
scopic residual disease) after the PAMP regimen.
Whereas WAR has proven to be useful as adjuvant
therapy in early ovarian cancer, its role in advanced
stage remains controversial. More recently published
results have even disclaimed a benefit for WAR in pa-
tients with residual disease after intensive chemother-
apy and second-look surgery [17, 18]. A randomized
trial in a small number of patients showed no difference
in survival [19]. The fact that only one randomized trial
has been published illustrates the difficulties of pro-
spectively planned multimodality treatments.
In our study WAR was hardly feasible for the major-
ity of the patients in remission, even after short-course
chemotherapy. This poor tolerance of WAR was in
contrast to reports from other authors who used doses
ranging between 22.5 and 27.5 Gy [17, 18]. We believe
that our dose and the restrictive rules defined by the
protocol in 1985 were the major reasons for poor tol-
erance/feasibility. The importance of the dose has been
confirmed by the findings of Rothenberg et al., who
employed a dose of 30 Gy and observed severe entero-
pathy [8]. The recommendation of Thomas to limit ab-
dominal radiotherapy to <25 Gy after first surgery,
chemotherapy and second-look seems therefore rea-
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sonable [20]. Another factor that may have influenced
the tolerance of WAR could be the use of melphalan,
which is known to be a potential stem cell killer en-
hancing myelosuppression. We note that about 2/3 of
the irradiated as well as non-irradiated patients in
remission relapsed. The majority of relapsing patients
were found to have diffuse peritoneal carcinosis. We
therefore believe that the addition of a pelvic boost, as
has been described by others, may not substantially
help to prevent relapse but may increase toxicity [20].
These results show that WAR as a consolidation treat-
ment cannot efficiently prevent relapse in patients with
pCR or cCR, nor can it be used as an efficient salvage
treatment for patients with microscopic residual dis-
ease after PAMP.
From these results we conclude that 4 cycles PAMP
were an effective treatment in early and advanced
ovarian cancer. WAR was hardly feasible as a consoli-
dation treatment for the majority of the patients in
remission, even after short-course chemotherapy. The
data allow no definitive conclusions about the role of
WAR because no randomization took place and a
selection bias may have influenced the data The total
dose delivered to the whole abdomen should probably
be below 29.9 Gy and previous chemotherapy should
be short. The current evaluation adds certainty to the
conclusions drawn in our first report For the majority
of patients, especially those with advanced disease, new
treatment modalities are needed.
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